About
Synthetically produced, human lysosomal protein
Areas of Focus
Categories
Biologics & BiopharmaceuticalSoutheastern U.S.
Team (6)
Catherine Pearce, DHSc, MBA
Bexion Pharmaceuticals
team_member
Charles R. Scheper
Bexion Pharmaceuticals
team_member
Keith A. Carlson
Bexion Pharmaceuticals
team_member
Olivia F. Kirtley, CPA, CGMA
Bexion Pharmaceuticals
team_member
Raymond J. Tesi, M.D.
Bexion Pharmaceuticals
team_member
Timothy Schroeder
Bexion Pharmaceuticals
team_member
Clinical Trials (7)
View allTotal Trials
7
As Lead Sponsor
7
As Collaborator
0
Total Enrollment
726
By Phase
PHASE3: 1PHASE1/PHASE2: 1EARLY_PHASE1: 1PHASE1: 4
By Status
TERMINATED: 3COMPLETED: 2RECRUITING: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline7 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT06911424Lead Sponsor
Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis
PHASE3Recruiting
400 participants
Started: Mar 21, 2025 · Completed: Dec 22, 2025
NCT05322590Lead Sponsor
BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma
PHASE1/PHASE2Active, not recruiting
195 participants
Started: Jan 9, 2023 · Completed: Apr 30, 2029
NCT05291286Lead Sponsor
BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients
EARLY_PHASE1Completed
21 participants
Started: Oct 17, 2022 · Completed: Dec 20, 2024
NCT04771897Lead Sponsor
A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)
PHASE1Terminated
10 participants
Started: May 24, 2021 · Completed: Oct 4, 2024
NCT04404569Lead Sponsor
Continued Treatment for Participants Enrolled in Studies of BXQ-350
PHASE1Terminated
5 participants
Started: Jun 8, 2020 · Completed: Sep 23, 2024
Locations (1)
Headquarters
Covington, KY, United States
Map
Loading map...